Aptose Biosciences Inc (NASDAQ:APTO) had its Buy rating reiterated by HC Wainwright with a $8.50 price target

Analyst Ratings For Aptose Biosciences Inc (NASDAQ:APTO)

Story continues below

Today, HC Wainwright reiterated its Buy rating on Aptose Biosciences Inc (NASDAQ:APTO) with a price target of $8.50.

There are 3 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Aptose Biosciences Inc (NASDAQ:APTO) is Buy with a consensus target price of $7.1667 per share, a potential 160.61% upside.

Some recent analyst ratings include

  • 8/8/2018-HC Wainwright Reiterated Rating of Buy.
  • 6/8/2017-Rodman & Renshaw initiated coverage with a Neutral rating.


    About Aptose Biosciences Inc (NASDAQ:APTO)
    Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

    Recent Trading Activity for Aptose Biosciences Inc (NASDAQ:APTO)
    Shares of Aptose Biosciences Inc closed the previous trading session at 2,75 −0,050 1,79 % with shares trading hands.

    An ad to help with our costs